Abstract Background: The development and molecular architecture of lung adenocarcinoma (LUAD) in never smokers (NS-LUAD) remain poorly understood. Spatial transcriptomics offers an opportunity to resolve tumor-microenvironment organization and detect spatially restricted cellular programs that may influence tumor evolution. Methods: We profiled LUAD and matched normal lung tissues using the 10x Xenium 5K platform in 15 NS-LUAD and 11 paired normal samples. For comparison, we also analyzed three LUAD and paired normal samples from smokers. To evaluate cross-platform reproducibility, eight adjacent tissue sections, including six from NS-LUAD and two from smokers, were also analyzed using the Visium HD platform. Spatial cellular composition, tumor-intrinsic cell states, and microenvironmental features were assessed using multiple computational approaches (e. g. SPARK-X, BANKSY, CellChat). Results: Across paired sections, we observed markedly reduced transcript capture in Visium HD compared with Xenium, despite high-quality Xenium data from the same tissues, suggesting that Visium HD may have reduced sensitivity in lung tissue, highlighting important platform-specific considerations. Analysis of Xenium datasets revealed substantial spatial heterogeneity among LUAD tumors, with differences associated with distinct driver gene alterations. NS-LUAD displayed spatially organized transcriptional programs and microenvironmental patterns that differed from those in smoker-associated LUAD. Conclusions: High-resolution Xenium-based spatial transcriptomics provides a robust framework to characterize spatial cellular architecture in LUAD and reveals distinct spatial features by smoking status. Ongoing analyses will refine tumor and immune cell-state definitions and identify spatial features linked to oncogenic drivers and disease evolution. Citation Format: Wei Zhao, Aaron Rozeboom, Phuc H. Hoang, Tam-Anh Tran, Maria Teresa Landi. High-resolution spatial transcriptomics identifies unique spatial programs in lung adenocarcinoma from never smokers abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts) ; 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86 (8Suppl): Abstract nr LB237.
Zhao et al. (2026) studied this question.